Globus Medical, Inc. shines with strong Q4 results & Nevro acquisition, boosting its market position. Click here to find out ...

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers. The medical ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical (GMED – Research Report) on April 15 and set a price target ...

Globus Medical GMED +0.38% Get Free Report has outperformed the market over the past 10 years by 1.4% on an annualized basis ...

The acquisition expands Globus Medical’s reach in the musculoskeletal market and the opportunity to add to its product portfolio. The deal was first announced in February, and Nevro was valued ...

Globus Medical has a fifty-two week low of $49.33 and a fifty-two week high of $94.93. Globus Medical ( NYSE:GMED – Get Free Report ) last posted its earnings results on Thursday, February 20th.

Globus Medical, Inc. GMED recently completed its previously disclosed acquisition of Nevro Corp., a global medical device company that delivers comprehensive, life-changing solutions for the ...

AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed ...